Oral surgical procedures and vitamin K antagonists. Treatment quality, complications and medication-related interactions.

Oral surgical procedures and vitamin K antagonists. Treatment quality, complications and medication-related interactions. - MKG_VKA

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00027916

Enrollment

250

Registered

2022-01-31

Start date

2021-03-25

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

K08.88 D68.3 T81.0 Z95.2

Interventions

Group 1: All consecutive patients with tooth extractions on oral vitamin K antagonist therapy.

Eligibility

Sex/Gender

All

Age

18 Years to 111 Years

Inclusion criteria

Inclusion criteria: Patients aged 18 and over Patients who are anticoagulated with a vitamin K antagonist for a pre-existing condition and require a simple dental surgical procedure (tooth extraction, even if this involves a localized osteotomy or intraoral abscess incision) Inpatient stay to monitor postoperative bleeding or secondary inpatient admission in the event of postoperative bleeding Inclusion period: 01/2018- 12/2020

Exclusion criteria

Exclusion criteria: Patients younger than 18 years. Other congenital or acquired coagulation disorders (also simultaneously), e.g. B. cirrhosis of the liver, von Willebrandt-Jürgens syndrome, therapy with direct oral anticoagulants (DOAC), sole therapy with platelet aggregation inhibitors. Extensive surgeries in the mouth, jaw and face (e.g. trauma, tumor, metal removal, abscess with extraoral incision), other dental surgical interventions e.g. wisdom tooth osteotomy, cystectomy, dental implantation, augmentation)

Design outcomes

Primary

Measure	Time frame
Occurrence of secondary bleeding after dento-alveolar surgical treatment and therapy with vitamin K antagonist.	—

Secondary

Measure	Time frame
A: Quality of Treatment: Is OAK therapy sufficient for inpatient admission? Is the INR in the target range for the corresponding underlying disease? Is the OAK therapy due to dental surgery bridged with low molecular weight heparins (LMWH)? B: Endocarditis prophylaxis Is this carried out consistently with the corresponding indication "heart valve replacement"? C: Complications How often does bleeding occur after tooth extractions under oral anticoagulation? Are there differences in the preoperative (target) INR value or the extent of the surgical intervention? D: Drug interactions Can an interaction with the OAK therapy be demonstrated in patients with endocarditis prophylaxis by an increase in the INR value in the postoperative course?	—

Measure

Time frame

A: Quality of Treatment: Is OAK therapy sufficient for inpatient admission? Is the INR in the target range for the corresponding underlying disease? Is the OAK therapy due to dental surgery bridged with low molecular weight heparins (LMWH)? B: Endocarditis prophylaxis Is this carried out consistently with the corresponding indication "heart valve replacement"? C: Complications How often does bleeding occur after tooth extractions under oral anticoagulation? Are there differences in the preoperative (target) INR value or the extent of the surgical intervention? D: Drug interactions Can an interaction with the OAK therapy be demonstrated in patients with endocarditis prophylaxis by an increase in the INR value in the postoperative course?

—

Countries

Germany

Contacts

Public ContactMichael Ermer

Uniklinik Freiburg Klinik für MKG Chirurgie

michael.ermer@uniklinik-freiburg.de076127047010

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026